Demographics of the cohorts.
| Variables | Development cohort (N=3,809) | Validation cohort (N=313) |
|---|---|---|
| Age at alloSCT, median, years (range) | 47 (18–74) | 48 (18–74) |
| <30 years, no (%) | 608 (16.0) | 57 (18.2) |
| 30–39 years, no (%) | 614 (16.1) | 60 (19.2) |
| 40–49 years, no (%) | 1,023 (26.9) | 61 (19.5) |
| 50–59 years, no (%) | 1,072 (28.1) | 78 (24.9) |
| 60–69 years, no (%) | 475 (12.5) | 51 (16.3) |
| ≥70 years, no (%) | 17 (0.4) | 6 (19.2) |
| Male, N (%) | 2,055 (54.0) | 152 (48.6) |
| Stem cell source | ||
| Bone marrow stem cell, N (%) | 469 (12.3) | 3 (1.0) |
| Mobilized peripheral blood stem cell, N (%) | 3,246 (85.2) | 310 (99.0) |
| Cord blood, N (%) | 94 (2.5) | 12 (3.8) |
| HCT-CI, median, points (range) | NA | 2 (0–8) |
| 0 (low-risk) | NA | 89 (28.4) |
| 1–2 (intermediate-risk) | NA | 126 (40.3) |
| ≥3 (high-risk) | NA | 98 (31.3) |
| Previous non-hematologic malignancy (%) | ||
| Yes | 387 (10.2) | 20 (6.3) |
| No | 3,422 (89.8) | 293 (93.6) |
| Hypertension (%) | ||
| Yes | 1,224 (32.1) | 74 (23.6) |
| No | 2,585 (67.9) | 239 (76.4) |
| Diabetes (%) | ||
| Yes | 1,125 (29.5) | 43 (13.7) |
| No | 2,684 (70.5) | 270 (86.3) |
| Dyslipidemia (%) | ||
| Yes | 2,135 (56.1) | 43 (13.7) |
| No | 1,674 (43.9) | 270 (86.3) |
| Chronic obstructive pulmonary disease (%) | ||
| Yes | 191 (5.0) | 7 (2.2) |
| No | 3,618 (95.0) | 306 (97.8) |
| Cerebrovascular or cardiovascular disease (%) | ||
| Yes | 166 (4.4) | 25 (8.0) |
| No | 3,643 (95.6) | 288 (92.0) |
| Anxiety disorder (%) | ||
| Yes | 900 (23.6) | 46 (14.7) |
| No | 2,909 (76.4) | 267 (85.3) |
| Depression (%) | ||
| Yes | 613 (16.1) | 35 (11.2) |
| No | 3,196 (83.9) | 278 (88.8) |
Abbreviations: alloSCT, allogeneic stem cell transplantation; HCT-CI, hematopoietic cell transplantation-specific comorbidity index; NA, not available.
Blood Res 2021;56:184~196 https://doi.org/10.5045/br.2021.2021107
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd